The Tinea Pedis (Athlete Foot) drugs in development market research report provides comprehensive information on the therapeutics under development for Tinea Pedis (Athlete Foot), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tinea Pedis (Athlete Foot). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tinea Pedis (Athlete Foot) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Tinea Pedis (Athlete Foot) by six companies/universities/institutes. The top development phase for Tinea Pedis (Athlete Foot) is phase ii with five drugs in that stage. The Tinea Pedis (Athlete Foot) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Tinea Pedis (Athlete Foot) pipeline products market are: DermBiont, Eisai and China Medical System.
The key targets in the Tinea Pedis (Athlete Foot) pipeline products market include Squalene Monooxygenase, and Lanosterol 14 Alpha Demethylase.
The key mechanisms of action in the Tinea Pedis (Athlete Foot) pipeline product include Squalene Monooxygenase Inhibitor with one drug in Phase II. The Tinea Pedis (Athlete Foot) pipeline products include three routes of administration with the top ROA being Topical and two key molecule types in the Tinea Pedis (Athlete Foot) pipeline products market including Small Molecule, and Biologic.
Tinea Pedis (Athlete Foot) overview
Athlete’s foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odor, and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.
For a complete picture of Tinea Pedis (Athlete Foot)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
